Jenscare Scientific Co., Ltd.

Equities

9877

CNE100005KC9

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. Other stock markets 09:09:05 07/06/2024 BST			5-day change	1st Jan Change
3.88 ^HKD	+2.65%		-2.27%	-82.52%

04-25	Jenscare Scientific's LuX-Valve Application Not Approved by NMPA, Share Prices Drop 11%	MT
03-27	Jenscare Scientific Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jenscare Scientific Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

March 28, 2023 at 03:54 pm

Jenscare Scientific Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CNY 439.31 million compared to CNY 500.52 million a year ago. Basic loss per share from continuing operations was CNY 1.2 compared to CNY 1.48 a year ago.

Latest news about Jenscare Scientific Co., Ltd.

Jenscare Scientific's LuX-Valve Application Not Approved by NMPA, Share Prices Drop 11%	04-25	MT
Jenscare Scientific Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Jenscare Scientific's Mitral Valve Device Completes Enrollment for Confirmatory Clinical Trials	03-25	MT
Jenscare Scientific Co., Ltd. Announces Completion of the Enrollment of JensClip for Confirmatory Clinical Trial and One-Month Follow-Up	03-25	CI
Jenscare Scientific Secures HKEX Nod for H Share Circulation	03-19	MT
Jenscare Scientific Co., Ltd. Completes the First Clinical Implantation in Brazil	02-28	CI
Jenscare Scientific’s CEO, CFO Boost Stake in Firm	01-26	MT
Jenscare Scientific Unit Concludes 1st Clinical Implantation of PFO Occluder System	01-03	MT
Jenscare Scientific Co., Ltd. Completes the First Clinical Implantation of Omniseal	01-03	CI
Jenscare Scientific to Buy Back Shares	12-29	MT
Jenscare Scientific Shareholders Approve of Sale of 22.48% Interest in Congenital Heart Disease Device Maker	12-22	MT
Jenscare Scientific to Divest 22.5% Stake in Medical Device Maker	11-29	MT
Jenscare Releases Results of Confirmatory Trial for Tricuspid Valve Replacement in London Meet	11-28	MT
Jenscare Scientific Co., Ltd. Announces One-Year Results of the Confirmatory Clinical Trial of the LuX-Valve Transcatheter Tricuspid Valve Replacement System	11-27	CI
Jenscare Scientific Enrolls First Patient for Atrial Appendage Occluder System Trial	11-13	MT
Jenscare Presents Results of Tricuspid Valve Replacement System at US Conference	31/10/23	MT
Jenscare Scientific Co., Ltd. Announces Lux-Valve Plus Travel II Results Released At the 2023 TCT in the U.S	30/10/23	CI
Jenscare Shares Surge 16% After China Grants Priority Approval for Aortic Heart Valve System	30/10/23	MT
Jenscare Scientific Co., Ltd. Announces Registration Application of Ken-Valve, the Transcatheter Prosthetic Aortic Heart Valve System Successfully Enters the Priority Approval Process	29/10/23	CI
Jenscare Scientific Applies Valve Replacement System Under Fee-for-Service Scheme in Asia-Pacific; Shares Tumble 9%	20/10/23	MT
Experts to Report on Clinical Trial of Jenscare Scientific's Valve Replacement System	19/10/23	MT
Jenscare Scientific Co., Ltd. Announces the Results of the Multicenter Clinical Trial of LuX-Valve Plus at the 2023 TCT in the U.S	18/10/23	CI
Jenscare's Lux-Valve Plus Selected for EMA Pilot Study	11/10/23	MT
Jenscare's Stock Drops Despite NMPA Acceptance for Ken-Valve Registration Application	11/10/23	MT
Jenscare Scientific Co., Ltd. Receives Confirmation Letter from the National Medical Products Administration of the People's Republic of China Confirms the Acceptance of the Registration Application for Ken-Valve	11/10/23	CI

Chart Jenscare Scientific Co., Ltd.

Duration

Period

More charts

Company Profile

Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The Company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The Company mainly conducts its businesses in the domestic market.

Sector

Medical Equipment, Supplies & Distribution

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.599 CNY

Average target price

36.69 CNY

Spread / Average Target

+919.43%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
JENSCARE SCIENTIFIC CO., LTD.	-82.52%	207M
SMITH & NEPHEW PLC	-3.76%	11.52B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-4.86%	8.3B
GLAUKOS CORPORATION	+43.30%	5.73B
INSPIRE MEDICAL SYSTEMS, INC.	-22.44%	4.69B
AXONICS, INC.	+7.79%	3.42B
ENOVIS CORPORATION	-17.26%	2.54B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-13.36%	2.03B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-16.39%	1.86B
DOUBLE MEDICAL TECHNOLOGY INC.	-31.24%	1.59B

Medical Devices & Implants